** Jefferies says Telix’s TLX.AX ProstACT trial for prostate cancer is progressing to a timely U.S. entry, with interim radiographic progression-free survival analysis data anticipated in 2027

** Medtech firm said on Thursday the U.S. drug regulator has cleared Part 2 of its global ProstACT trial for U.S. expansion, deeming Part 1 safety data adequate

** Brokerage further expects the Investigational New Drug amendment to be approved, clearing U.S. recruitment for the randomised portion of the Phase 3 study

** ProstACT trial is being done to investigate TLX591 as a targeted therapy for metastatic castration‑resistant prostate cancer

** Stock up 53.4% YTD